Jump to content

Ombitasvir

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ozzie10aaaa (talk | contribs) at 16:48, 28 January 2023 (Cleaned up using AutoEd). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ombitasvir
Clinical data
Trade names
  • Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir),
  • Technivie (with ombitasvir, paritaprevir, and ritonavir)
Other namesABT-267
License data
Routes of
administration		By mouth (tablets)
Legal status
Legal status
Pharmacokinetic data
BioavailabilityNot determined
Protein binding~99.9%
MetabolismAmide hydrolysis followed by oxidation
Onset of action~4 to 5 hours
Elimination half-life21 to 25 hours
ExcretionMostly with feces (90.2%)
Identifiers
  • Dimethyl N,N′-{[(2S,5S)-1-(4-tert-butylphenyl)pyrrolidene-2,5-diyl]-bis-{[(4,1-phenyleneazanediyl)carbonyl] [(2S)-pyrrolidine-2,1-diyl]}[(2S)-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC50H67N7O8
Molar mass894.127 g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
  • InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
  • Key:PIDFDZJZLOTZTM-KHVQSSSXSA-N

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1,[1][2] and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.[3][4]

Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.[5]

See also

References

  1. ^ "VIEKIRA PAK™ (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Retrieved 30 July 2015.
  2. ^ "FDA approves Viekira Pak to treat hepatitis C". Food and Drug Administration. December 19, 2014.
  3. ^ "TECHNIVIE™ (ombitasvir, paritaprevir and ritonavir) Tablets, for Oral Use. Full Prescribing Information" (PDF). AbbVie Inc., North Chicago, IL 60064. Archived from the original (PDF) on 19 January 2019. Retrieved 28 July 2015.
  4. ^ "FDA approves Technivie for treatment of chronic hepatitis C genotype 4". Food and Drug Administration. July 24, 2015.
  5. ^ Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. (April 2014). "Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin" (PDF). The New England Journal of Medicine. 370 (17): 1594–603. doi:10.1056/NEJMoa1315722. PMID 24720703.

Further reading

Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Ombitasvir&oldid=1136076248"